GLP-1 drugs achieve some of these effects by directly affecting the brain’s cravings for food, and that might also extend to cravings for alcohol, said senior researcher Dr. Carel le Roux, chair of experimental pathology at University College Dublin in Ireland.

A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a serious form of fatty liver disease, a new study has found.

First-generation GLP-1 weight-loss drugs can help reduce the risk of obesity-related cancers, new research shows. Liraglutide, exenatide, and dulaglutide were 41% more effective at preventing obesity-related cancers.

New research has found that GLP-1 drugs can substantially reduce the risk of obesity-related cancers — and they’re more effective than getting weight loss surgery.

Weight-loss injections, or GLP-1 receptor agonists, could nearly halve the risk of obesity-related cancers, a new study finds amid rising global obesity rates.

Former FDA Commissioner David Kessler shared his experience with GLP-1 weight loss drugs on "CBS Mornings Plus."

New research being presented at the European Congress on Obesity (ECO25) in Malaga, Spain (11–14 May) and published in the journal eClinicalMedicine finds that first-generation weight-loss medications like liraglutide and exenatide appear to show anti-cancer benefits beyond weight loss.

While GLP-1 receptor agonists and bariatric surgery offer significant metabolic benefits, experts caution that rapid weight loss may trigger emotional instability in vulnerable individuals.

The trends worry health experts, who say the medicines have potential to narrow differences in obesity rates among demographic groups, but may in fact be widening them.

David Kessler has lost more than 60 pounds on weight-loss drugs and believes they can change the trajectory of chronic disease in the United States.